View Future GrowthAptose Biosciences 過去の業績過去 基準チェック /06Aptose Biosciences は平均年間 19% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。30% です。主要情報18.99%収益成長率37.81%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024May 08Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024Mar 19Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023Oct 27Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023Jul 29すべての更新を表示Recent updatesAptose Biosciences Inc.'s Tuspetinib Triple Drug Therapy Featured At the 2025 ASH Annual MeetingDec 06Hanmi Pharm. Co., Ltd. (KOSE:A128940) entered into a definitive arrangement agreement to acquire remaining 80.07% stake in Aptose Biosciences Inc. (TSX:APS) for CAD 4.9 million.Nov 19Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AMLOct 16Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY TrialAug 19Aptose Biosciences Inc. Enrollment Is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug TherapyAug 07The Nasdaq Stock Market to Delist the Common Shares of Aptose BiosciencesJul 14Aptose Biosciences Inc. Announces Resignation of Carol Ashe as Director, Effective June 16, 2025Jun 18Aptose Biosciences Inc. Presents Safety, Response, and MRD Clinical Data from Tuspetinib Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA CongressJun 12Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy After Dose Escalation Decision by Safety Review CommitteeMay 20Aptose Biosciences Inc. Selects for Oral Presentation of Data from Tuscany Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed Aml At the 2025 Eha CongressMay 15Aptose Provides Clinical Update for the Tuspetinib-Based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY TrialMay 06Nasdaq Determined to Delist Aptose Biosciences' Securities from The Nasdaq Stock Market, Effective on April 2, 2025Apr 04Aptose Biosciences Inc.(OTCPK:APTO.F) dropped from NASDAQ Composite IndexApr 03Aptose Biosciences Inc., Annual General Meeting, Jun 12, 2025Apr 01New major risk - Revenue and earnings growth Mar 28Aptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceMar 18New major risk - Market cap size Feb 20Aptose Announces Positive Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortFeb 20Aptose Announces Reverse Share Split to Regain Compliance with Minimum Bid Price RequirementFeb 19Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 Tuscany TrialFeb 12Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $1 million.Feb 04Aptose Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price RequirementJan 22Aptose Biosciences Inc. Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialJan 10Aptose Biosciences Inc. Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on Aml Cells When Combined with VenetoclaxDec 13Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLDec 10Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $8 million.Nov 27Aptose Biosciences Inc. Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-Based Triplet TherapyNov 20New major risk - Financial position Nov 17Price target decreased by 36% to US$7.00 Oct 28Aptose Biosciences Receives Staff Determination Letter from Nasdaq Due to Failure to Meet the Terms of an ExtensionOct 06New major risk - Market cap size Aug 12New major risk - Negative shareholders equity Aug 11New minor risk - Share price stability Aug 09Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $10 million.Aug 02Aptose Announces Receipt of Deficiency Notice from NasdaqJul 20Aptose Biosciences Inc. has completed a Follow-on Equity Offering.Jun 05New major risk - Revenue and earnings growth Jun 02Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million.Jun 01New major risk - Financial position May 16Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024May 08Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)Apr 07New major risk - Negative shareholders equity Mar 27Aptose Biosciences Inc., Annual General Meeting, May 28, 2024Mar 20Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024Mar 19Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLCMar 04New major risk - Shareholder dilution Jan 28Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.Jan 27+ 1 more updateAptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.Jan 26Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingDec 11Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business OfficerDec 01Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingNov 04Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOct 31Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023Oct 27Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30thOct 24New major risk - Share price stability Oct 17Independent Director recently bought US$53k worth of stock Sep 26Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, TuspetinibAug 25New minor risk - Share price stability Aug 13Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.Aug 11Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023Jul 29Aptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceJun 27Aptose Biosciences Inc. Presents Highlights from Clinical UpdateJun 13Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in fundingMay 26Forecast to breakeven in 2025 May 10Aptose Biosciences Inc. Announces the 120 Mg Monotherapy Dosing of Patients in the Aptivate Phase 1/2 Clinical Trial of Tuspetinib (Formerly Hm43239), an Oral, Mutation Agnostic Tyrosine Kinase Inhibitor (Tki) Being Developed for the Treatment of Patients with Relapsed or Refractory Acute Myeloid LeukemiaJan 31Insufficient new directors Oct 31Aptose Biosciences Q2 2022 Earnings Preview Aug 01Aptose Biosciences Continues To Drift Without Thesis-Changing Data Jul 19Insufficient new directors Apr 27Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress Feb 02収支内訳Aptose Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:APTO.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-25131130 Sep 250-1912730 Jun 250-21121031 Mar 250-21111131 Dec 240-25111530 Sep 240-36122530 Jun 240-40132831 Mar 240-47143431 Dec 230-51163730 Sep 230-49163430 Jun 230-48163331 Mar 230-44163031 Dec 220-42152830 Sep 220-56154230 Jun 220-58154331 Mar 220-61164531 Dec 210-65194630 Sep 210-56213530 Jun 210-58233531 Mar 210-60293231 Dec 200-55262930 Sep 200-48232630 Jun 200-42202331 Mar 200-32141931 Dec 190-26101730 Sep 190-25101630 Jun 190-2491531 Mar 190-2891931 Dec 180-29101930 Sep 180-2691730 Jun 180-2391431 Mar 180-158831 Dec 170-126630 Sep 170-115630 Jun 170-126631 Mar 170-146831 Dec 160-146830 Sep 160-157830 Jun 160-147731 Mar 160-127601 Jan 160-1285質の高い収益: APTO.Fは現在利益が出ていません。利益率の向上: APTO.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: APTO.Fは利益を出していないが、過去 5 年間で年間19%の割合で損失を削減してきた。成長の加速: APTO.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: APTO.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: APTO.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 06:58終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aptose Biosciences Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Matthew VeneziaAlliance Global PartnersDylan DupuisB. Riley Securities, Inc.John NewmanCanaccord Genuity6 その他のアナリストを表示
Aptose Biosciences Inc.'s Tuspetinib Triple Drug Therapy Featured At the 2025 ASH Annual MeetingDec 06
Hanmi Pharm. Co., Ltd. (KOSE:A128940) entered into a definitive arrangement agreement to acquire remaining 80.07% stake in Aptose Biosciences Inc. (TSX:APS) for CAD 4.9 million.Nov 19
Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AMLOct 16
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY TrialAug 19
Aptose Biosciences Inc. Enrollment Is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug TherapyAug 07
Aptose Biosciences Inc. Announces Resignation of Carol Ashe as Director, Effective June 16, 2025Jun 18
Aptose Biosciences Inc. Presents Safety, Response, and MRD Clinical Data from Tuspetinib Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA CongressJun 12
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy After Dose Escalation Decision by Safety Review CommitteeMay 20
Aptose Biosciences Inc. Selects for Oral Presentation of Data from Tuscany Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed Aml At the 2025 Eha CongressMay 15
Aptose Provides Clinical Update for the Tuspetinib-Based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY TrialMay 06
Nasdaq Determined to Delist Aptose Biosciences' Securities from The Nasdaq Stock Market, Effective on April 2, 2025Apr 04
Aptose Announces Positive Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortFeb 20
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 Tuscany TrialFeb 12
Aptose Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price RequirementJan 22
Aptose Biosciences Inc. Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialJan 10
Aptose Biosciences Inc. Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on Aml Cells When Combined with VenetoclaxDec 13
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLDec 10
Aptose Biosciences Inc. Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-Based Triplet TherapyNov 20
Aptose Biosciences Receives Staff Determination Letter from Nasdaq Due to Failure to Meet the Terms of an ExtensionOct 06
Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million.Jun 01
Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)Apr 07
Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.Jan 27+ 1 more update
Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.Jan 26
Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOct 31
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30thOct 24
Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, TuspetinibAug 25
Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.Aug 11
Aptose Biosciences Inc. Announces the 120 Mg Monotherapy Dosing of Patients in the Aptivate Phase 1/2 Clinical Trial of Tuspetinib (Formerly Hm43239), an Oral, Mutation Agnostic Tyrosine Kinase Inhibitor (Tki) Being Developed for the Treatment of Patients with Relapsed or Refractory Acute Myeloid LeukemiaJan 31